Growth hormone deficiency and replacement in patients with treated Cushing's disease, prolactinomas and non-functioning pituitary adenomas: Effects on body composition, glucose metabolism, lipid status and bone mineral density

Hormone Research

Volumn 66, Issue 6, 2006, Pages 257-267

  Colson, A ^a   Brooke, A M ^a   Walker, D ^a   Besser, G M ^a   Chew, S L ^a   Grossman, A B ^a   Jenkins, P J ^a   Drake, W M ^a   Monson, J P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cushing's disease; Growth hormone replacement therapy; Non functioning pituitary adenoma; Prolactinoma

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBOHYDRATE; CHOLESTEROL; CORTICOSTEROID; DESMOPRESSIN; DOPAMINE RECEPTOR STIMULATING AGENT; ETIDRONIC ACID; FIBRIC ACID DERIVATIVE; FOLLITROPIN; GLICLAZIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SEX HORMONE; SOMATOMEDIN C; THYROXINE; TRIACYLGLYCEROL; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CUSHING DISEASE; DRUG EFFECT; DRUG INDICATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HIP; HORMONE SUBSTITUTION; HUMAN; HYPERMETABOLISM; HYPOGONADISM; HYPOPHYSIS ADENOMA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTINOMA; QUALITATIVE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; WAIST HIP RATIO;

ADENOMA; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMAN GROWTH HORMONE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; PROLACTINOMA; PROSPECTIVE STUDIES;

EID: 33751330912     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095168     Document Type: Article

References (35)

1. Bengtsson BÅ, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Ståhl E, Westberg B, Wilton P, Wüster C: The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. J Clin Endocrinol Metab 1999;84:3929-3935.
2. Johannsson G, Sunnerhagen KS, Svensson J: Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clin Endocrinol 2004;60:350-359.
3. Feldt-Rasmussen U, Abs R, Bramnert M, Bengtsson B-Å, Monson JP, Wüster C, Bennmarker H, Hernberg-Ståhl E, Westberg B, Wilton P: Growth hormone deficiency in patients treated for acromegaly or Cushing's disease. Eur J Endocrinol 2001;146:67-74.
4. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Boseus I, Bengtsson BÅ, Johannsson G: A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001;86:4657-4665.
5. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sönksen PH, Russell-Jones D: The effect of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999;84:2596-2602.
6. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff B, Murphy M, Thomas E, Robinson S, Foale R, Johnston DG: Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000;85:3762-3769.
7. Svensson J, Fowelin J, Landin K, Bengtsson BÅ, Johansson JO: Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002;87:2121-2127.
8. Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL, Grossman AB, Besser GM, Monson JP: Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol 2000;53:453-459.
9. Rosenfalck AM, Maghsoudi S, Fisker S, Jørgensen JOL, Christiansen JS, Hilsted J, Volund AA, Madsbad S: The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and c-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000;85:4173-4181.
10. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J: The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995;80:153-159.
11. Binnerts A, Swart GR, Wilson J, Hoogerbrugge N, Pols H, Birkenhager JC, Lamberts S: The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol 1992;37:79-87.
12. Fowelin J, Attvall S, Lager I, Bengtsson BÅ: Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993;42:1443-1447.
13. O'Neal DN, Kalfas A, Dunning PL: The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab 1994;79:975-983.
14. Whitehead HM, Boreham C, Mcllrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR: Growth hormone treatment of adults with growth hormone deficiency: results of a 13-months placebo controlled cross over study. Clin Endocrinol 1992;39:45-52.
15. Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A: A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990;5:609-618.
16. Johansen JP, Pedersen SA, Jørgensen JOL, Riis BJ, Christiansen C, Christiansen JS, Skakkebaek NE: Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults. J Clin Endocrinol Metab 1990;70:916-919.
17. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ, Hintz RL, Sherman BM: Effects of short-term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990;70:519-527.
18. Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thoren M: Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000;85:4104-4112.
19. Drake WM, Rodrigues-Arnao J, Weaver IT, James D, Coyte T, Spector G, Besser M, Monson JP: The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol 2001;54:525-532.
20. Clanget C, Seck T, Hinke V, Wuster C, Ziegler R, Pleilschifter J: Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol 2001;55:93-99.
21. Vandeweghe M, Taelman P, Kaufman JM: Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol 1993;39:409-415.
22. Degerbald M, Elgindy N, Hall K, Sjoberg HE, Thorén M: Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol 1992;126:387-393.
23. O'Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM: Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993;76:1344-1348.
24. Morrell DJ, Dadi H, More J, Taylor AM, Dabestani A, Buchanan CR, Holder AT, Preece MA: A monoclonal antibody to human insulin-like growth factor-I: characterisation, use in radioimmunoassay and effect on the biological activities of the growth factor. Mol J Endocrinol 1989;2:201-206.
25. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Drake WM, Coyte D, Kaltsas G, Camacho-Hübner C, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP: Optimising growth hormone replacement by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998;83:3913-3919.
27. Hwu CM, Kwok CF, Lai TY, Shih KC, Lee TS, Hsiao LC, Lee SH, Fang VS, Ho LT: Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997;82:3285-3292.
28. Russell-Jones DL, Weissberger AJ, Bowes SB: The effects of growth hormone on protein metabolism in adult growth hormone deficient patients. Clin Endocrinol 1993;38:427-431.
29. Mukherjee A, Murray RD, Shalet SM: Impact of growth hormone status on body composition and the skelet. Horm Res 2004;62(suppl 3):35-41.
30. Kuromaru R, Kohno H, Ueyama N, Hassan HM, Hara T: Long-term effect of growth hormone (GH) treatment on body composition in children with GH deficiency. Endocr J 1999;46:35-38.
31. Kehely A, Bates PC, Frewer P, Birkett M, Blum WF, Mamessier P, Ezzat S, Ho KK, Lombardi G, Luger A, Marek J, Russell-Jones D, Sonksen P, Attanasio AF: Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 2002;87:1974-1979.
32. Bengtsson BÅ, Éden S, Lonn L: Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309-317.
33. Copeland KC, Nair KS: Acute growth hormone effects on amino acid and lipid metabolism. J Clin Endocrinol Metab 1994;78:1040-1047.
34. Salomon F, Cuneo RC, Hesp R, Sönksen PH: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797-1803.
35. Pearce EN: Hypothyroidism and dyslipidemia: Modern concept and approaches. Curr Cardiol Rep 2004;6:451-456.